Translating biological findings into new treatment strategies for amyotrophic lateral sclerosis (ALS)

Experimental Neurology

Volumn 262, Issue Part B, 2014, Pages 138-151

  Poppe, Lindsay ^a,b   Rué, Laura ^a,b   Robberecht, Wim ^a,b,c   Van Den Bosch, Ludo ^a,b  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Clinical trials; Motoneuron; Motor neuron disease; Neurodegeneration; Therapy

Indexed keywords

CD11B ANTIGEN; CEFTRIAXONE; CELECOXIB; COPPER ZINC SUPEROXIDE DISMUTASE; DYNACTIN; DYNEIN ADENOSINE TRIPHOSPHATASE; EPHRIN A4; FUSED IN SARCOMA PROTEIN; GLATIRAMER; GLIAL FIBRILLARY ACIDIC PROTEIN; GLUTAMATE TRANSPORTER; MINOCYCLINE; NEUROTROPHIC FACTOR; OZANEZUMAB; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PROTEIN NOGO A; RILUZOLE; SEMAPHORIN; SUPEROXIDE DISMUTASE; TAR DNA BINDING PROTEIN; VASCULOTROPIN;

AMYOTROPHIC LATERAL SCLEROSIS; ANTIANGIOGENIC ACTIVITY; ASTROCYTE; ASTROCYTOSIS; AUTOPHAGOSOME; AUTOPHAGY; CELL DEATH; CELL DIFFERENTIATION; CELL SURVIVAL; DEGENERATIVE DISEASE; DISEASE COURSE; DISEASE SEVERITY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; EXCITOTOXICITY; GENE EXPRESSION; GENE SILENCING; GLIA CELL; GLIOSIS; HUMAN; MICROGLIA; MITOCHONDRIAL DYNAMICS; MITOCHONDRIAL RESPIRATION; MOTONEURON; NERVE CELL; NERVE DEGENERATION; NERVE FIBER TRANSPORT; NERVE SPROUTING; NEUROMUSCULAR SYNAPSE; NONHUMAN; OLIGODENDROGLIA; PATHOGENESIS; PHENOTYPE; PHENOTYPIC VARIATION; PLURIPOTENT STEM CELL; PROTEIN FUNCTION; REGULATORY T LYMPHOCYTE; REPRODUCIBILITY; REVIEW; RISK FACTOR; RNA PROCESSING; RNA SPLICING; SOD1 GENE; SPINOCEREBELLAR DEGENERATION; SYMPTOMATOLOGY; TDP 43 PROTEINOPATHY; TRANSGENE; ANIMAL; DISEASE MODEL; PROCEDURES; TRANSLATIONAL RESEARCH;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84908390975     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2014.07.001     Document Type: Review

References (220)

1. Acsadi G., Anguelov R.A., Yang H., Toth G., Thomas R., Jani A., Wang Y., Ianakova E., Mohammad S., Lewis R.A., Shy M.E. Increased survival and function of SOD1 mice after glial cell-derived neurotrophic factor gene therapy. Hum. Gene Ther. 2002, 13:1047-1059.
2. Afifi A.K., Aleu F.P., Goodgold J., MacKay B. Ultrastructure of atrophic muscle in amyotrophic lateral sclerosis. Neurology 1966, 16:475-481.
3. Al-Chalabi A., Jones A., Troakes C., King A., Al-Sarraj S., van den Berg L.H. The genetics and neuropathology of amyotrophic lateral sclerosis. Acta Neuropathol. 2012, 124:339-352.
4. Alexianu M.E., Kozovska M., Appel S.H. Immune reactivity in a mouse model of familial ALS correlates with disease progression. Neurology 2001, 57:1282-1289.
5. Almeida S., Gascon E., Tran H., Chou H.J., Gendron T.F., Degroot S., Tapper A.R., Sellier C., Charlet-Berguerand N., Karydas A., Seeley W.W., Boxer A.L., Petrucelli L., Miller B.L., Gao F.B. Modeling key pathological features of frontotemporal dementia with C9ORF72 repeat expansion in iPSC-derived human neurons. Acta Neuropathol. 2013, 126:385-399.
6. Aoki N., Higashi S., Kawakami I., Kobayashi Z., Hosokawa M., Katsuse O., Togo T., Hirayasu Y., Akiyama H. Localization of fused in sarcoma (FUS) protein to the post-synaptic density in the brain. Acta Neuropathol. 2012, 124:383-394.
7. Armakola M., Higgins M.J., Figley M.D., Barmada S.J., Scarborough E.A., Diaz Z., Fang X., Shorter J., Krogan N.J., Finkbeiner S., Farese R.V., Gitler A.D. Inhibition of RNA lariat debranching enzyme suppresses TDP-43 toxicity in ALS disease models. Nat. Genet. 2012, 44:1302-1309.
8. Ash P.E., Bieniek K.F., Gendron T.F., Caulfield T., Lin W.L., Dejesus-Hernandez M., van Blitterswijk M.M., Jansen-West K., Paul J.W., Rademakers R., Boylan K.B., Dickson D.W., Petrucelli L. Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS. Neuron 2013, 77:639-646.
9. Azzouz M., Ralph G.S., Storkebaum E., Walmsley L.E., Mitrophanous K.A., Kingsman S.M., Carmeliet P., Mazarakis N.D. VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature 2004, 429:413-417.
10. Banerjee R., Beal M.F., Thomas B. Autophagy in neurodegenerative disorders: pathogenic roles and therapeutic implications. Trends Neurosci. 2010, 33:541-549.
11. Beers D.R., Henkel J.S., Xiao Q., Zhao W., Wang J., Yen A.A., Siklos L., McKercher S.R., Appel S.H. Wild-type microglia extend survival in PU.1 knockout mice with familial amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:16021-16026.
12. Beers D.R., Henkel J.S., Zhao W., Wang J., Appel S.H. CD4+ T cells support glial neuroprotection, slow disease progression, and modify glial morphology in an animal model of inherited ALS. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:15558-15563.
13. Beers D.R., Henkel J.S., Zhao W., Wang J., Huang A., Wen S., Liao B., Appel S.H. Endogenous regulatory T lymphocytes ameliorate amyotrophic lateral sclerosis in mice and correlate with disease progression in patients with amyotrophic lateral sclerosis. Brain J. Neurol. 2011, 134:1293-1314.
14. Bensimon G., Lacomblez L., Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N. Engl. J. Med. 1994, 330:585-591.
15. Bensimon G., Lacomblez L., Delumeau J.C., Bejuit R., Truffinet P., Meininger V., Riluzole A.L.S.S. A study of riluzole in the treatment of advanced stage or elderly patients with amyotrophic lateral sclerosis. J. Neurol. 2002, 249:609-615.
16. Berry J.D., Shefner J.M., Conwit R., Schoenfeld D., Keroack M., Felsenstein D., Krivickas L., David W.S., Vriesendorp F., Pestronk A., Caress J.B., Katz J., Simpson E., Rosenfeld J., Pascuzzi R., Glass J., Rezania K., Rothstein J.D., Greenblatt D.J., Cudkowicz M.E., Northeast A.L.S.C. Design and initial results of a multi-phase randomized trial of ceftriaxone in amyotrophic lateral sclerosis. PLoS One 2013, 8:e61177.
17. Bhattacharya A., Bokov A., Muller F.L., Jernigan A.L., Maslin K., Diaz V., Richardson A., Van Remmen H. Dietary restriction but not rapamycin extends disease onset and survival of the H46R/H48Q mouse model of ALS. Neurobiol. Aging 2012, 33:1829-1832.
18. Bilican B., Serio A., Barmada S.J., Nishimura A.L., Sullivan G.J., Carrasco M., Phatnani H.P., Puddifoot C.A., Story D., Fletcher J., Park I.H., Friedman B.A., Daley G.Q., Wyllie D.J., Hardingham G.E., Wilmut I., Finkbeiner S., Maniatis T., Shaw C.E., Chandran S. Mutant induced pluripotent stem cell lines recapitulate aspects of TDP-43 proteinopathies and reveal cell-specific vulnerability. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:5803-5808.
19. Blasco H., Bernard-Marissal N., Vourc'h P., Guettard Y.O., Sunyach C., Augereau O., Khederchah J., Mouzat K., Antar C., Gordon P.H., Veyrat-Durebex C., Besson G., Andersen P.M., Salachas F., Meininger V., Camu W., Pettmann B., Andres C.R., Corcia P., French A.L.S.S. A rare motor neuron deleterious missense mutation in the DPYSL3 (CRMP4) gene is associated with ALS. Hum. Mutat. 2013, 34:953-960.
20. Bogaert E., Van Damme P., Van Den Bosch L., Robberecht W. Vascular endothelial growth factor in amyotrophic lateral sclerosis and other neurodegenerative diseases. Muscle Nerve 2006, 34:391-405.
21. Bogaert E., Van Damme P., Poesen K., Dhondt J., Hersmus N., Kiraly D., Scheveneels W., Robberecht W., Van Den Bosch L. VEGF protects motor neurons against excitotoxicity by upregulation of GluR2. Neurobiol. Aging 2010, 31:2185-2191.
22. Boillee S., Yamanaka K., Lobsiger C.S., Copeland N.G., Jenkins N.A., Kassiotis G., Kollias G., Cleveland D.W. Onset and progression in inherited ALS determined by motor neurons and microglia. Science 2006, 312:1389-1392.
23. Bordet T., Buisson B., Michaud M., Drouot C., Galea P., Delaage P., Akentieva N.P., Evers A.S., Covey D.F., Ostuni M.A., Lacapere J.J., Massaad C., Schumacher M., Steidl E.M., Maux D., Delaage M., Henderson C.E., Pruss R.M. Identification and characterization of cholest-4-en-3-one, oxime (TRO19622), a novel drug candidate for amyotrophic lateral sclerosis. J. Pharmacol. Exp. Ther. 2007, 322:709-720.
24. Burkhardt M.F., Martinez F.J., Wright S., Ramos C., Volfson D., Mason M., Garnes J., Dang V., Lievers J., Shoukat-Mumtaz U., Martinez R., Gai H., Blake R., Vaisberg E., Grskovic M., Johnson C., Irion S., Bright J., Cooper B., Nguyen L., Griswold-Prenner I., Javaherian A. A cellular model for sporadic ALS using patient-derived induced pluripotent stem cells. Mol. Cell. Neurosci. 2013, 56:355-364.
25. Burrell J.R., Kiernan M.C., Vucic S., Hodges J.R. Motor neuron dysfunction in frontotemporal dementia. Brain J. Neurol. 2011, 134:2582-2594.
26. Carmeliet P., Storkebaum E. Vascular and neuronal effects of VEGF in the nervous system: implications for neurological disorders. Semin. Cell Dev. Biol. 2002, 13:39-53.
27. Castillo K., Nassif M., Valenzuela V., Rojas F., Matus S., Mercado G., Court F.A., van Zundert B., Hetz C. Trehalose delays the progression of amyotrophic lateral sclerosis by enhancing autophagy in motoneurons. Autophagy 2013, 9:1308-1320.
28. Chiu I.M., Chen A., Zheng Y., Kosaras B., Tsiftsoglou S.A., Vartanian T.K., Brown R.H., Carroll M.C. T lymphocytes potentiate endogenous neuroprotective inflammation in a mouse model of ALS. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:17913-17918.
29. Clement A.M., Nguyen M.D., Roberts E.A., Garcia M.L., Boillee S., Rule M., McMahon A.P., Doucette W., Siwek D., Ferrante R.J., Brown R.H., Julien J.P., Goldstein L.S., Cleveland D.W. Wild-type nonneuronal cells extend survival of SOD1 mutant motor neurons in ALS mice. Science 2003, 302:113-117.
30. Collard J.F., Cote F., Julien J.P. Defective axonal-transport in a transgenic mouse model of amyotrophic-lateral-sclerosis. Nature 1995, 375:61-64.
31. Cudkowicz M.E., McKennaYasek D., Sapp P.E., Chin W., Geller B., Hayden D.L., Schoenfeld D.A., Hosler B.A., Horvitz H.R., Brown R.H. Epidemiology of mutations in superoxide dismutase in amyotrophic lateral sclerosis. Ann. Neurol. 1997, 41:210-221.
32. Cudkowicz M.E., Shefner J.M., Schoenfeld D.A., Zhang H., Andreasson K.I., Rothstein J.D., Drachman D.B. Trial of celecoxib in amyotrophic lateral sclerosis. Ann. Neurol. 2006, 60:22-31.
33. Cudkowicz M., Shefner J., Consortium N. STAGE 3 clinical trial of ceftriaxone in subjects with ALS (S36.001). Neurology 2012, 80:S36.001.
34. Cudkowicz M.E., van den Berg L.H., Shefner J.M., Mitsumoto H., Mora J.S., Ludolph A., Hardiman O., Bozik M.E., Ingersoll E.W., Archibald D., Meyers A.L., Dong Y., Farwell W.R., Kerr D.A., Investigators, E. Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial. Lancet Neurol. 2013, 12:1059-1067.
35. Da Cruz S., Parone P.A., Lopes V.S., Lillo C., McAlonis-Downes M., Lee S.K., Vetto A.P., Petrosyan S., Marsala M., Murphy A.N., Williams D.S., Spiegelman B.M., Cleveland D.W. Elevated PGC-1alpha activity sustains mitochondrial biogenesis and muscle function without extending survival in a mouse model of inherited ALS. Cell Metab. 2012, 15:778-786.
36. De Vos K.J., Chapman A.L., Tennant M.E., Manser C., Tudor E.L., Lau K.F., Brownlees J., Ackerley S., Shaw P.J., McLoughlin D.M., Shaw C.E., Leigh P.N., Miller C.C., Grierson A.J. Familial amyotrophic lateral sclerosis-linked SOD1 mutants perturb fast axonal transport to reduce axonal mitochondria content. Hum. Mol. Genet. 2007, 16:2720-2728.
37. De Vos K.J., Grierson A.J., Ackerley S., Miller C.C.J. Role of axonal transport in neurodegenerative diseases. Annu. Rev. Neurosci. 2008, 31:151-173.
38. De Winter F., Vo T., Stam F.J., Wisman L.A., Bar P.R., Niclou S.P., van Muiswinkel F.L., Verhaagen J. The expression of the chemorepellent Semaphorin 3A is selectively induced in terminal Schwann cells of a subset of neuromuscular synapses that display limited anatomical plasticity and enhanced vulnerability in motor neuron disease. Mol. Cell. Neurosci. 2006, 32:102-117.
39. DeJesus-Hernandez M., Mackenzie I.R., Boeve B.F., Boxer A.L., Baker M., Rutherford N.J., Nicholson A.M., Finch N.A., Flynn H., Adamson J., Kouri N., Wojtas A., Sengdy P., Hsiung G.Y., Karydas A., Seeley W.W., Josephs K.A., Coppola G., Geschwind D.H., Wszolek Z.K., Feldman H., Knopman D.S., Petersen R.C., Miller B.L., Dickson D.W., Boylan K.B., Graff-Radford N.R., Rademakers R. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 2011, 72:245-256.
40. Deng H.X., Chen W., Hong S.T., Boycott K.M., Gorrie G.H., Siddique N., Yang Y., Fecto F., Shi Y., Zhai H., Jiang H., Hirano M., Rampersaud E., Jansen G.H., Donkervoort S., Bigio E.H., Brooks B.R., Ajroud K., Sufit R.L., Haines J.L., Mugnaini E., Pericak-Vance M.A., Siddique T. Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia. Nature 2011, 477:211-215.
41. Dewey C.M., Cenik B., Sephton C.F., Dries D.R., Mayer P., Good S.K., Johnson B.A., Herz J., Yu G. TDP-43 is directed to stress granules by sorbitol, a novel physiological osmotic and oxidative stressor. Mol. Cell. Biol. 2011, 31:1098-1108.
42. Di Giorgio F.P., Carrasco M.A., Siao M.C., Maniatis T., Eggan K. Non-cell autonomous effect of glia on motor neurons in an embryonic stem cell-based ALS model. Nat. Neurosci. 2007, 10:608-614.
43. Dimos J.T., Rodolfa K.T., Niakan K.K., Weisenthal L.M., Mitsumoto H., Chung W., Croft G.F., Saphier G., Leibel R., Goland R., Wichterle H., Henderson C.E., Eggan K. Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science 2008, 321:1218-1221.
44. Dobrowolny G., Giacinti C., Pelosi L., Nicoletti C., Winn N., Barberi L., Molinaro M., Rosenthal N., Musaro A. Muscle expression of a local Igf-1 isoform protects motor neurons in an ALS mouse model. J. Cell Biol. 2005, 168:193-199.
45. Dodge J.C., Treleaven C.M., Fidler J.A., Hester M., Haidet A., Handy C., Rao M., Eagle A., Matthews J.C., Taksir T.V., Cheng S.H., Shihabuddin L.S., Kaspar B.K. AAV4-mediated expression of IGF-1 and VEGF within cellular components of the ventricular system improves survival outcome in familial ALS mice. Mol. Ther. 2010, 18:2075-2084.
46. Dolmetsch R., Geschwind D.H. The human brain in a dish: the promise of iPSC-derived neurons. Cell 2011, 145:831-834.
47. Donnelly C.J., Zhang P.W., Pham J.T., Heusler A.R., Mistry N.A., Vidensky S., Daley E.L., Poth E.M., Hoover B., Fines D.M., Maragakis N., Tienari P.J., Petrucelli L., Traynor B.J., Wang J., Rigo F., Bennett C.F., Blackshaw S., Sattler R., Rothstein J.D. RNA toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense intervention. Neuron 2013, 80:415-428.
48. Dormann D., Rodde R., Edbauer D., Bentmann E., Fischer I., Hruscha A., Than M.E., Mackenzie I.R., Capell A., Schmid B., Neumann M., Haass C. ALS-associated fused in sarcoma (FUS) mutations disrupt transportin-mediated nuclear import. EMBO J. 2010, 29:2841-2857.
49. Dottori M., Hartley L., Galea M., Paxinos G., Polizzotto M., Kilpatrick T., Bartlett P.F., Murphy M., Kontgen F., Boyd A.W. EphA4 (Sek1) receptor tyrosine kinase is required for the development of the corticospinal tract. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:13248-13253.
50. Drachman D.B., Frank K., Dykes-Hoberg M., Teismann P., Almer G., Przedborski S., Rothstein J.D. Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS. Ann. Neurol. 2002, 52:771-778.
51. Dupuis L., Gonzalez de Aguilar J.L., di Scala F., Rene F., de Tapia M., Pradat P.F., Lacomblez L., Seihlan D., Prinjha R., Walsh F.S., Meininger V., Loeffler J.P. Nogo provides a molecular marker for diagnosis of amyotrophic lateral sclerosis. Neurobiol. Dis. 2002, 10:358-365.
52. d'Ydewalle C., Krishnan J., Chiheb D.M., Van Damme P., Irobi J., Kozikowski A.P., Vanden Berghe P., Timmerman V., Robberecht W., Van Den Bosch L. HDAC6 inhibitors reverse axonal loss in a mouse model of mutant HSPB1-induced Charcot-Marie-Tooth disease. Nat. Med. 2011, 17:968-U986.
53. Eberhart J., Swartz M.E., Koblar S.A., Pasquale E.B., Krull C.E. EphA4 constitutes a population-specific guidance cue for motor neurons. Dev. Biol. 2002, 247:89-101.
54. Egawa N., Kitaoka S., Tsukita K., Naitoh M., Takahashi K., Yamamoto T., Adachi F., Kondo T., Okita K., Asaka I., Aoi T., Watanabe A., Yamada Y., Morizane A., Takahashi J., Ayaki T., Ito H., Yoshikawa K., Yamawaki S., Suzuki S., Watanabe D., Hioki H., Kaneko T., Makioka K., Okamoto K., Takuma H., Tamaoka A., Hasegawa K., Nonaka T., Hasegawa M., Kawata A., Yoshida M., Nakahata T., Takahashi R., Marchetto M.C., Gage F.H., Yamanaka S., Inoue H. Drug screening for ALS using patient-specific induced pluripotent stem cells. Sci. Transl. Med. 2012, 4:145ra104.
55. Ekestern E. Neurotrophic factors and amyotrophic lateral sclerosis. Neurodegener. Dis. 2004, 1:88-100.
56. Elden A.C., Kim H.J., Hart M.P., Chen-Plotkin A.S., Johnson B.S., Fang X., Armakola M., Geser F., Greene R., Lu M.M., Padmanabhan A., Clay-Falcone D., McCluskey L., Elman L., Juhr D., Gruber P.J., Rub U., Auburger G., Trojanowski J.Q., Lee V.M., Van Deerlin V.M., Bonini N.M., Gitler A.D. Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature 2010, 466:1069-1075.
57. Engelhardt J.I., Tajti J., Appel S.H. Lymphocytic infiltrates in the spinal cord in amyotrophic lateral sclerosis. Arch. Neurol. 1993, 50:30-36.
58. Eschbach J., Schwalenstocker B., Soyal S.M., Bayer H., Wiesner D., Akimoto C., Nilsson A.C., Birve A., Meyer T., Dupuis L., Danzer K.M., Andersen P.M., Witting A., Ludolph A.C., Patsch W., Weydt P. PGC-1alpha is a male-specific disease modifier of human and experimental amyotrophic lateral sclerosis. Hum. Mol. Genet. 2013, 22:3477-3484.
59. Fallini C., Bassell G.J., Rossoll W. The ALS disease protein TDP-43 is actively transported in motor neuron axons and regulates axon outgrowth. Hum. Mol. Genet. 2012, 21:3703-3718.
60. Fanara P., Banerjee J., Hueck R.V., Harper M.R., Awada M., Turner H., Husted K.H., Brandt R., Hellerstein M.K. Stabilization of hyperdynamic microtubules is neuroprotective in amyotrophic lateral sclerosis. J. Biol. Chem. 2007, 282:23465-23472.
61. Fecto F., Yan J., Vemula S.P., Liu E., Yang Y., Chen W., Zheng J.G., Shi Y., Siddique N., Arrat H., Donkervoort S., Ajroud-Driss S., Sufit R.L., Heller S.L., Deng H.X., Siddique T. SQSTM1 mutations in familial and sporadic amyotrophic lateral sclerosis. Arch. Neurol. 2011, 68:1440-1446.
62. Fecto F., Esengul Y.T., Deng H.X., Siddique T. Autophagy is impaired by UBQLN2 mutations linked to ALS/FTD. Neurology 2012, 78.
63. Fischer L.R., Culver D.G., Tennant P., Davis A.A., Wang M., Castellano-Sanchez A., Khan J., Polak M.A., Glass J.D. Amyotrophic lateral sclerosis is a distal axonopathy: evidence in mice and man. Exp. Neurol. 2004, 185:232-240.
64. Franz C.K., Federici T., Yang J., Backus C., Oh S.S., Teng Q., Carlton E., Bishop K.M., Gasmi M., Bartus R.T., Feldman E.L., Boulis N.M. Intraspinal cord delivery of IGF-I mediated by adeno-associated virus 2 is neuroprotective in a rat model of familial ALS. Neurobiol. Dis. 2009, 33:473-481.
65. Fratta P., Mizielinska S., Nicoll A.J., Zloh M., Fisher E.M., Parkinson G., Isaacs A.M. C9orf72 hexanucleotide repeat associated with amyotrophic lateral sclerosis and frontotemporal dementia forms RNA G-quadruplexes. Sci. Reports 2012, 2:1016.
66. Frey D., Schneider C., Xu L., Borg J., Spooren W., Caroni P. Early and selective loss of neuromuscular synapse subtypes with low sprouting competence in motoneuron diseases. J. Neurosci. Off. J. Soc. Neurosci. 2000, 20:2534-2542.
67. Fritz E., Izaurieta P., Weiss A., Mir F.R., Rojas P., Gonzalez D., Rojas F., Brown R.H., Madrid R., van Zundert B. Mutant SOD1-expressing astrocytes release toxic factors that trigger motoneuron death by inducing hyperexcitability. J. Neurophysiol. 2013, 109:2803-2814.
68. Furrer S.A., Waldherr S.M., Mohanachandran M.S., Baughn T.D., Nguyen K.T., Sopher B.L., Damian V.A., Garden G.A., La Spada A.R. Reduction of mutant ataxin-7 expression restores motor function and prevents cerebellar synaptic reorganization in a conditional mouse model of SCA7. Hum. Mol. Genet. 2013, 22:890-903.
69. Galbussera A., Tremolizzo L., Brighina L., Testa D., Lovati R., Ferrarese C., Cavaletti G., Filippini G. Vitamin E intake and quality of life in amyotrophic lateral sclerosis patients: a follow-up case series study. Neurol. Sci. Off. J. Ital. Neurol. Soc. Ital. Soc. Clin. Neurophysiol. 2006, 27:190-193.
70. Gao Z., Tsirka S.E. Animal models of MS reveal multiple roles of microglia in disease pathogenesis. Neurol. Res. Int. 2011, 2011:383087.
71. Gendron T.F., Bieniek K.F., Zhang Y.J., Jansen-West K., Ash P.E.A., Caulfield T., Daughrity L., Dunmore J.H., Castanedes-Casey M., Chew J., Cosio D.M., van Blitterswijk M., Lee W.C., Rademakers R., Boylan K.B., Dickson D.W., Petrucelli L. Antisense transcripts of the expanded C9ORF72 hexanucleotide repeat form nuclear RNA foci and undergo repeat-associated non-ATG translation in c9FTD/ALS. Acta Neuropathol. 2013, 126:829-844.
72. Giacomotto J., Segalat L. High-throughput screening and small animal models, where are we?. Br. J. Pharmacol. 2010, 160:204-216.
73. Gijselinck I., Van Langenhove T., van der Zee J., Sleegers K., Philtjens S., Kleinberger G., Janssens J., Bettens K., Van Cauwenberghe C., Pereson S., Engelborghs S., Sieben A., De Jonghe P., Vandenberghe R., Santens P., De Bleecker J., Maes G., Baumer V., Dillen L., Joris G., Cuijt I., Corsmit E., Elinck E., Van Dongen J., Vermeulen S., Van den Broeck M., Vaerenberg C., Mattheijssens M., Peeters K., Robberecht W., Cras P., Martin J.J., De Deyn P.P., Cruts M., Van Broeckhoven C. A C9orf72 promoter repeat expansion in a Flanders-Belgian cohort with disorders of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrum: a gene identification study. Lancet Neurol. 2012, 11:54-65.
74. Goldshmit Y., Galea M.P., Wise G., Bartlett P.F., Turnley A.M. Axonal regeneration and lack of astrocytic gliosis in EphA4-deficient mice. J. Neurosci. Off. J. Soc. Neurosci. 2004, 24:10064-10073.
75. Gong Y.H., Parsadanian A.S., Andreeva A., Snider W.D., Elliott J.L. Restricted expression of G86R Cu/Zn superoxide dismutase in astrocytes results in astrocytosis but does not cause motoneuron degeneration. J. Neurosci. Off. J. Soc. Neurosci. 2000, 20:660-665.
76. Gordon P.H., Moore D.H., Miller R.G., Florence J.M., Verheijde J.L., Doorish C., Hilton J.F., Spitalny G.M., MacArthur R.B., Mitsumoto H., Neville H.E., Boylan K., Mozaffar T., Belsh J.M., Ravits J., Bedlack R.S., Graves M.C., McCluskey L.F., Barohn R.J., Tandan R., Western A.L.S.S. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol. 2007, 6:1045-1053.
77. Gowing G., Philips T., Van Wijmeersch B., Audet J.N., Dewil M., Van Den Bosch L., Billiau A.D., Robberecht W., Julien J.P. Ablation of proliferating microglia does not affect motor neuron degeneration in amyotrophic lateral sclerosis caused by mutant superoxide dismutase. J. Neurosci. Off. J. Soc. Neurosci. 2008, 28:10234-10244.
78. Gros-Louis F., Soucy G., Lariviere R., Julien J.P. Intracerebroventricular infusion of monoclonal antibody or its derived Fab fragment against misfolded forms of SOD1 mutant delays mortality in a mouse model of ALS. J. Neurochem. 2010, 113:1188-1199.
79. Gurney M.E., Pu H.F., Chiu A.Y., Dalcanto M.C., Polchow C.Y., Alexander D.D., Caliendo J., Hentati A., Kwon Y.W., Deng H.X., Chen W.J., Zhai P., Sufit R.L., Siddique T. Motor-neuron degeneration in mice that express a human Cu, Zn superoxide-dismutase mutation. Science 1994, 264:1772-1775.
80. Haidet-Phillips A.M., Hester M.E., Miranda C.J., Meyer K., Braun L., Frakes A., Song S., Likhite S., Murtha M.J., Foust K.D., Rao M., Eagle A., Kammesheidt A., Christensen A., Mendell J.R., Burghes A.H., Kaspar B.K. Astrocytes from familial and sporadic ALS patients are toxic to motor neurons. Nat. Biotechnol. 2011, 29:824-828.
81. Hall E.D., Oostveen J.A., Gurney M.E. Relationship of microglial and astrocytic activation to disease onset and progression in a transgenic model of familial ALS. Glia 1998, 23:249-256.
82. Hara T., Nakamura K., Matsui M., Yamamoto A., Nakahara Y., Suzuki-Migishima R., Yokoyama M., Mishima K., Saito I., Okano H., Mizushima N. Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice. Nature 2006, 441:885-889.
83. Henkel J.S., Beers D.R., Wen S., Rivera A.L., Toennis K.M., Appel J.E., Zhao W., Moore D.H., Powell S.Z., Appel S.H. Regulatory T-lymphocytes mediate amyotrophic lateral sclerosis progression and survival. EMBO Mol. Med. 2013, 5:64-79.
84. Henriques A., Pitzer C., Schneider A. Neurotrophic growth factors for the treatment of amyotrophic lateral sclerosis: where do we stand?. Front. Neurosci. 2010, 4:32.
85. Hetz C., Thielen P., Matus S., Nassif M., Court F., Kiffin R., Martinez G., Cuervo A.M., Brown R.H., Glimcher L.H. XBP-1 deficiency in the nervous system protects against amyotrophic lateral sclerosis by increasing autophagy. Genes Dev. 2009, 23:2294-2306.
86. Higgins C.M., Jung C., Xu Z. ALS-associated mutant SOD1G93A causes mitochondrial vacuolation by expansion of the intermembrane space and by involvement of SOD1 aggregation and peroxisomes. BMC Neurosci. 2003, 4:16.
87. Howland D.S., Liu J., She Y., Goad B., Maragakis N.J., Kim B., Erickson J., Kulik J., DeVito L., Psaltis G., DeGennaro L.J., Cleveland D.W., Rothstein J.D. Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutant-mediated amyotrophic lateral sclerosis (ALS). Proc. Natl. Acad. Sci. U. S. A. 2002, 99:1604-1609.
88. Huang C., Tong J., Bi F., Zhou H., Xia X.G. Mutant TDP-43 in motor neurons promotes the onset and progression of ALS in rats. J. Clin. Invest. 2012, 122:107-118.
89. Hwang D.H., Lee H.J., Park I.H., Seok J.I., Kim B.G., Joo I.S., Kim S.U. Intrathecal transplantation of human neural stem cells overexpressing VEGF provide behavioral improvement, disease onset delay and survival extension in transgenic ALS mice. Gene Ther. 2009, 16:1234-1244.
90. Ikenaka K., Kawai K., Katsuno M., Huang Z., Jiang Y.M., Iguchi Y., Kobayashi K., Kimata T., Waza M., Tanaka F., Mori I., Sobue G. dnc-1/dynactin 1 knockdown disrupts transport of autophagosomes and induces motor neuron degeneration. PLoS One 2013, 8:e54511.
91. Johnson B.S., Snead D., Lee J.J., McCaffery J.M., Shorter J., Gitler A.D. TDP-43 is intrinsically aggregation-prone, and amyotrophic lateral sclerosis-linked mutations accelerate aggregation and increase toxicity. J. Biol. Chem. 2009, 284:20329-20339.
92. Jokic N., Gonzalez de Aguilar J.L., Pradat P.F., Dupuis L., Echaniz-Laguna A., Muller A., Dubourg O., Seilhean D., Hauw J.J., Loeffler J.P., Meininger V. Nogo expression in muscle correlates with amyotrophic lateral sclerosis severity. Ann. Neurol. 2005, 57:553-556.
93. Jokic N., Gonzalez de Aguilar J.L., Dimou L., Lin S., Fergani A., Ruegg M.A., Schwab M.E., Dupuis L., Loeffler J.P. The neurite outgrowth inhibitor Nogo-A promotes denervation in an amyotrophic lateral sclerosis model. EMBO Rep. 2006, 7:1162-1167.
94. Jouroukhin Y., Ostritsky R., Assaf Y., Pelled G., Giladi E., Gozes I. NAP (davunetide) modifies disease progression in a mouse model of severe neurodegeneration: protection against impairments in axonal transport. Neurobiol. Dis. 2013, 56:79-94.
95. Kang S.H., Li Y., Fukaya M., Lorenzini I., Cleveland D.W., Ostrow L.W., Rothstein J.D., Bergles D.E. Degeneration and impaired regeneration of gray matter oligodendrocytes in amyotrophic lateral sclerosis. Nat. Neurosci. 2013, 16:571-579.
96. Kaspar B.K., Llado J., Sherkat N., Rothstein J.D., Gage F.H. Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science 2003, 301:839-842.
97. Kaufmann P., Thompson J.L., Levy G., Buchsbaum R., Shefner J., Krivickas L.S., Katz J., Rollins Y., Barohn R.J., Jackson C.E., Tiryaki E., Lomen-Hoerth C., Armon C., Tandan R., Rudnicki S.A., Rezania K., Sufit R., Pestronk A., Novella S.P., Heiman-Patterson T., Kasarskis E.J., Pioro E.P., Montes J., Arbing R., Vecchio D., Barsdorf A., Mitsumoto H., Levin B., Q.S.Group Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III. Ann. Neurol. 2009, 66:235-244.
98. Kawaguchi Y., Kovacs J.J., McLaurin A., Vance J.M., Ito A., Yao T.P. The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell 2003, 115:727-738.
99. Kawamata H., Manfredi G. Mitochondrial dysfunction and intracellular calcium dysregulation in ALS. Mech. Ageing Dev. 2010, 131:517-526.
100. Keller A.F., Gravel M., Kriz J. Treatment with minocycline after disease onset alters astrocyte reactivity and increases microgliosis in SOD1 mutant mice. Exp. Neurol. 2011, 228:69-79.
101. Kieran D., Hafezparast M., Bohnert S., Dick J.R., Martin J., Schiavo G., Fisher E.M., Greensmith L. A mutation in dynein rescues axonal transport defects and extends the life span of ALS mice. J. Cell Biol. 2005, 169:561-567.
102. Kigerl K.A., Gensel J.C., Ankeny D.P., Alexander J.K., Donnelly D.J., Popovich P.G. Identification of two distinct macrophage subsets with divergent effects causing either neurotoxicity or regeneration in the injured mouse spinal cord. J. Neurosci. Off. J. Soc. Neurosci. 2009, 29:13435-13444.
103. Kim J., Kim T.Y., Cho K.S., Kim H.N., Koh J.Y. Autophagy activation and neuroprotection by progesterone in the G93A-SOD1 transgenic mouse model of amyotrophic lateral sclerosis. Neurobiol. Dis. 2013, 59:80-85.
104. Komatsu M., Waguri S., Chiba T., Murata S., Iwata J., Tanida I., Ueno T., Koike M., Uchiyama Y., Kominami E., Tanaka K. Loss of autophagy in the central nervous system causes neurodegeneration in mice. Nature 2006, 441:880-884.
105. Kong J., Xu Z. Massive mitochondrial degeneration in motor neurons triggers the onset of amyotrophic lateral sclerosis in mice expressing a mutant SOD1. J. Neurosci. Off. J. Soc. Neurosci. 1998, 18:3241-3250.
106. Kriz J., Nguyen M.D., Julien J.P. Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis. Neurobiol. Dis. 2002, 10:268-278.
107. Kwiatkowski T.J., Bosco D.A., Leclerc A.L., Tamrazian E., Vanderburg C.R., Russ C., Davis A., Gilchrist J., Kasarskis E.J., Munsat T., Valdmanis P., Rouleau G.A., Hosler B.A., Cortelli P., de Jong P.J., Yoshinaga Y., Haines J.L., Pericak-Vance M.A., Yan J., Ticozzi N., Siddique T., McKenna-Yasek D., Sapp P.C., Horvitz H.R., Landers J.E., Brown R.H. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 2009, 323:1205-1208.
108. Lacomblez L., Bensimon G., Leigh P.N., Guillet P., Meininger V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet 1996, 347:1425-1431.
109. Lagier-Tourenne C., Polymenidou M., Hutt K.R., Vu A.Q., Baughn M., Huelga S.C., Clutario K.M., Ling S.C., Liang T.Y., Mazur C., Wancewicz E., Kim A.S., Watt A., Freier S., Hicks G.G., Donohue J.P., Shiue L., Bennett C.F., Ravits J., Cleveland D.W., Yeo G.W. Divergent roles of ALS-linked proteins FUS/TLS and TDP-43 intersect in processing long pre-mRNAs. Nat. Neurosci. 2012, 15:1488-1497.
110. Lambrechts D., Storkebaum E., Morimoto M., Del-Favero J., Desmet F., Marklund S.L., Wyns S., Thijs V., Andersson J., van Marion I., Al-Chalabi A., Bornes S., Musson R., Hansen V., Beckman L., Adolfsson R., Pall H.S., Prats H., Vermeire S., Rutgeerts P., Katayama S., Awata T., Leigh N., Lang-Lazdunski L., Dewerchin M., Shaw C., Moons L., Vlietinck R., Morrison K.E., Robberecht W., Van Broeckhoven C., Collen D., Andersen P.M., Carmeliet P. VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat. Genet. 2003, 34:383-394.
111. LaMonte B.H., Wallace K.E., Holloway B.A., Shelly S.S., Ascano J., Tokito M., Van Winkle T., Howland D.S., Holzbaur E.L. Disruption of dynein/dynactin inhibits axonal transport in motor neurons causing late-onset progressive degeneration. Neuron 2002, 34:715-727.
112. Lee E.B., Lee V.M.Y., Trojanowski J.Q. Gains or losses: molecular mechanisms of TDP43-mediated neurodegeneration. Nat. Rev. Neurosci. 2012, 13:38-50.
113. Lee Y., Morrison B.M., Li Y., Lengacher S., Farah M.H., Hoffman P.N., Liu Y., Tsingalia A., Jin L., Zhang P.W., Pellerin L., Magistretti P.J., Rothstein J.D. Oligodendroglia metabolically support axons and contribute to neurodegeneration. Nature 2012, 487:443-448.
114. Lee Y.B., Chen H.J., Peres J.N., Gomez-Deza J., Attig J., Stalekar M., Troakes C., Nishimura A.L., Scotter E.L., Vance C., Adachi Y., Sardone V., Miller J.W., Smith B.N., Gallo J.M., Ule J., Hirth F., Rogelj B., Houart C., Shaw C.E. Hexanucleotide repeats in ALS/FTD form length-dependent RNA foci, sequester RNA binding proteins, and are neurotoxic. Cell Rep. 2013, 5:1178-1186.
115. Leigh P.N., Meininger V., Bensimon G., Cudkowicz M., Robberecht W. Minocycline for patients with ALS. Lancet Neurol. 2008, 7:119-120.
116. Lemmens R., Van Hoecke A., Hersmus N., Geelen V., D'Hollander I., Thijs V., Van Den Bosch L., Carmeliet P., Robberecht W. Overexpression of mutant superoxide dismutase 1 causes a motor axonopathy in the zebrafish. Hum. Mol. Genet. 2007, 16:2359-2365.
117. Lemmens R., Moore M.J., Al-Chalabi A., Brown R.H., Robberecht W. RNA metabolism and the pathogenesis of motor neuron diseases. Trends Neurosci. 2010, 33:249-258.
118. Lemmens R., Jaspers T., Robberecht W., Thijs V.N. Modifying expression of EphA4 and its downstream targets improves functional recovery after stroke. Hum. Mol. Genet. 2013, 22:2214-2220.
119. Lepore A.C., Haenggeli C., Gasmi M., Bishop K.M., Bartus R.T., Maragakis N.J., Rothstein J.D. Intraparenchymal spinal cord delivery of adeno-associated virus IGF-1 is protective in the SOD1G93A model of ALS. Brain Res. 2007, 1185:256-265.
120. Lepore A.C., Rauck B., Dejea C., Pardo A.C., Rao M.S., Rothstein J.D., Maragakis N.J. Focal transplantation-based astrocyte replacement is neuroprotective in a model of motor neuron disease. Nat. Neurosci. 2008, 11:1294-1301.
121. Lepore A.C., O'Donnell J., Kim A.S., Williams T., Tuteja A., Rao M.S., Kelley L.L., Campanelli J.T., Maragakis N.J. Human glial-restricted progenitor transplantation into cervical spinal cord of the SOD1 mouse model of ALS. PLoS One 2011, 6:e25968.
122. Levine T.P., Daniels R.D., Gatta A.T., Wong L.H., Hayes M.J. The product of C9orf72, a gene strongly implicated in neurodegeneration, is structurally related to DENN Rab-GEFs. Bioinformatics 2013, 29:499-503.
123. Li L., Zhang X., Le W. Altered macroautophagy in the spinal cord of SOD1 mutant mice. Autophagy 2008, 4:290-293.
124. Liang H., Ward W.F., Jang Y.C., Bhattacharya A., Bokov A.F., Li Y., Jernigan A., Richardson A., Van Remmen H. PGC-1alpha protects neurons and alters disease progression in an amyotrophic lateral sclerosis mouse model. Muscle Nerve 2011, 44:947-956.
125. Liao B., Zhao W., Beers D.R., Henkel J.S., Appel S.H. Transformation from a neuroprotective to a neurotoxic microglial phenotype in a mouse model of ALS. Exp. Neurol. 2012, 237:147-152.
126. Lillo P., Hodges J.R. Frontotemporal dementia and motor neurone disease: overlapping clinic-pathological disorders. J. Clin. Neurosci. Off. J. Neurosurg. Soc. Australas. 2009, 16:1131-1135.
127. Lino M.M., Schneider C., Caroni P. Accumulation of SOD1 mutants in postnatal motoneurons does not cause motoneuron pathology or motoneuron disease. J. Neurosci. Off. J. Soc. Neurosci. 2002, 22:4825-4832.
128. Liu H.N., Tjostheim S., Dasilva K., Taylor D., Zhao B., Rakhit R., Brown M., Chakrabartty A., McLaurin J., Robertson J. Targeting of monomer/misfolded SOD1 as a therapeutic strategy for amyotrophic lateral sclerosis. J. Neurosci. Off. J. Soc. Neurosci. 2012, 32:8791-8799.
129. Lobsiger C.S., Cleveland D.W. Glial cells as intrinsic components of non-cell-autonomous neurodegenerative disease. Nat. Neurosci. 2007, 10:1355-1360.
130. Lomen-Hoerth C., Anderson T., Miller B. The overlap of amyotrophic lateral sclerosis and frontotemporal dementia. Neurology 2002, 59:1077-1079.
131. Lu L., Zheng L., Viera L., Suswam E., Li Y., Li X., Estevez A.G., King P.H. Mutant Cu/Zn-superoxide dismutase associated with amyotrophic lateral sclerosis destabilizes vascular endothelial growth factor mRNA and downregulates its expression. J. Neurosci. Off. J. Soc. Neurosci. 2007, 27:7929-7938.
132. Ludolph A.C., Bendotti C., Blaugrund E., Chio A., Greensmith L., Loeffler J.P., Mead R., Niessen H.G., Petri S., Pradat P.F., Robberecht W., Ruegg M., Schwalenstocker B., Stiller D., van den Berg L., Vieira F., von Horsten S. Guidelines for preclinical animal research in ALS/MND: a consensus meeting. Amyotroph. Lateral Scler. Off. Publ. World Fed. Neurol. Res. Group Mot. Neuron Dis. 2010, 11:38-45.
133. Magnus T., Carmen J., Deleon J., Xue H., Pardo A.C., Lepore A.C., Mattson M.P., Rao M.S., Maragakis N.J. Adult glial precursor proliferation in mutant SOD1G93A mice. Glia 2008, 56:200-208.
134. Martin L.J. Olesoxime, a cholesterol-like neuroprotectant for the potential treatment of amyotrophic lateral sclerosis. IDrugs Investig. Drugs J. 2010, 13:568-580.
135. McDonald K.K., Aulas A., Destroismaisons L., Pickles S., Beleac E., Camu W., Rouleau G.A., Vande Velde C. TAR DNA-binding protein 43 (TDP-43) regulates stress granule dynamics via differential regulation of G3BP and TIA-1. Hum. Mol. Genet. 2011, 20:1400-1410.
136. McGoldrick P., Joyce P.I., Fisher E.M.C., Greensmith L. Rodent models of amyotrophic lateral sclerosis. BBA Mol. Basis Dis. 2013, 1832:1421-1436.
137. Meininger V., Drory V.E., Leigh P.N., Ludolph A., Robberecht W., Silani V. Glatiramer acetate has no impact on disease progression in ALS at 40mg/day: a double-blind, randomized, multicentre, placebo-controlled trial. Amyotroph. Lateral Scler.Off. Publ. World Fed. Neurol. Res. Group Mot. Neuron Dis. 2009, 10:378-383.
138. Millecamps S., Julien J.P. Axonal transport deficits and neurodegenerative diseases. Nat. Rev. Neurosci. 2013, 14:161-176.
139. Miller R.G., Mitchell J.D., Lyon M., Moore D.H. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst. Rev. 2007, CD001447.
140. Miller R.G., Mitchell J.D., Moore D.H. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst. Rev. 2012, 3:CD001447.
141. Miller T.M., Pestronk A., David W., Rothstein J., Simpson E., Appel S.H., Andres P.L., Mahoney K., Allred P., Alexander K., Ostrow L.W., Schoenfeld D., Macklin E.A., Norris D.A., Manousakis G., Crisp M., Smith R., Bennett C.F., Bishop K.M., Cudkowicz M.E. An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study. Lancet Neurol. 2013, 12:435-442.
142. Mori K., Arzberger T., Grasser F.A., Gijselinck I., May S., Rentzsch K., Weng S.M., Schludi M.H., van der Zee J., Cruts M., Van Broeckhoven C., Kremmer E., Kretzschmar H.A., Haass C., Edbauer D. Bidirectional transcripts of the expanded C9orf72 hexanucleotide repeat are translated into aggregating dipeptide repeat proteins. Acta Neuropathol. 2013, 126:881-893.
143. Mori K., Weng S.M., Arzberger T., May S., Rentzsch K., Kremmer E., Schmid B., Kretzschmar H.A., Cruts M., Van Broeckhoven C., Haass C., Edbauer D. The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD/ALS. Science 2013, 339:1335-1338.
144. Morimoto N., Nagai M., Ohta Y., Miyazaki K., Kurata T., Morimoto M., Murakami T., Takehisa Y., Ikeda Y., Kamiya T., Abe K. Increased autophagy in transgenic mice with a G93A mutant SOD1 gene. Brain Res. 2007, 1167:112-117.
145. Munch C., Sedlmeier R., Meyer T., Homberg V., Sperfeld A.D., Kurt A., Prudlo J., Peraus G., Hanemann C.O., Stumm G., Ludolph A.C. Point mutations of the p150 subunit of dynactin (DCTN1) gene in ALS. Neurology 2004, 63:724-726.
146. Munro K.M., Dixon K.J., Gresle M.M., Jonas A., Kemper D., Doherty W., Fabri L.J., Owczarek C.M., Pearse M., Boyd A.W., Kilpatrick T.J., Butzkueven H., Turnley A.M. EphA4 receptor tyrosine kinase is a modulator of onset and disease severity of experimental autoimmune encephalomyelitis (EAE). PLoS One 2013, 8:e55948.
147. Nagai M., Re D.B., Nagata T., Chalazonitis A., Jessell T.M., Wichterle H., Przedborski S. Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons. Nat. Neurosci. 2007, 10:615-622.
148. Nagano I., Ilieva H., Shiote M., Murakami T., Yokoyama M., Shoji M., Abe K. Therapeutic benefit of intrathecal injection of insulin-like growth factor-1 in a mouse model of amyotrophic lateral sclerosis. J. Neurol. Sci. 2005, 235:61-68.
149. Neumann M., Sampathu D.M., Kwong L.K., Truax A.C., Micsenyi M.C., Chou T.T., Bruce J., Schuck T., Grossman M., Clark C.M., McCluskey L.F., Miller B.L., Masliah E., Mackenzie I.R., Feldman H., Feiden W., Kretzschmar H.A., Trojanowski J.Q., Lee V.M. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006, 314:130-133.
150. Nixon R.A. The role of autophagy in neurodegenerative disease. Nat. Med. 2013, 19:983-997.
151. Okamoto K., Hirai S., Shoji M., Senoh Y., Yamazaki T. Axonal swellings in the corticospinal tracts in amyotrophic lateral sclerosis. Acta Neuropathol. 1990, 80:222-226.
152. Oosthuyse B., Moons L., Storkebaum E., Beck H., Nuyens D., Brusselmans K., Van Dorpe J., Hellings P., Gorselink M., Heymans S., Theilmeier G., Dewerchin M., Laudenbach V., Vermylen P., Raat H., Acker T., Vleminckx V., Van Den Bosch L., Cashman N., Fujisawa H., Drost M.R., Sciot R., Bruyninckx F., Hicklin D.J., Ince C., Gressens P., Lupu F., Plate K.H., Robberecht W., Herbert J.M., Collen D., Carmeliet P. Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat. Genet. 2001, 28:131-138.
153. Park S., Kim H.T., Yun S., Kim I.S., Lee J., Lee I.S., Park K.I. Growth factor-expressing human neural progenitor cell grafts protect motor neurons but do not ameliorate motor performance and survival in ALS mice. Exp. Mol. Med. 2009, 41:487-500.
154. Parone P.A., Da Cruz S., Han J.S., McAlonis-Downes M., Vetto A.P., Lee S.K., Tseng E., Cleveland D.W. Enhancing mitochondrial calcium buffering capacity reduces aggregation of misfolded SOD1 and motor neuron cell death without extending survival in mouse models of inherited amyotrophic lateral sclerosis. J. Neurosci. Off. J. Soc. Neurosci. 2013, 33:4657-4671.
155. Pastula D.M., Moore D.H., Bedlack R.S. Creatine for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst. Rev. 2012, 12:CD005225.
156. Perrin S. Preclinical research: make mouse studies work. Nature 2014, 507:423-425.
157. Philips T., Robberecht W. Neuroinflammation in amyotrophic lateral sclerosis: role of glial activation in motor neuron disease. Lancet Neurol. 2011, 10:253-263.
158. Philips T., Bento-Abreu A., Nonneman A., Haeck W., Staats K., Geelen V., Hersmus N., Kusters B., Van Den Bosch L., Van Damme P., Richardson W.D., Robberecht W. Oligodendrocyte dysfunction in the pathogenesis of amyotrophic lateral sclerosis. Brain J Neurol. 2013, 136:471-482.
159. Poesen K., Lambrechts D., Van Damme P., Dhondt J., Bender F., Frank N., Bogaert E., Claes B., Heylen L., Verheyen A., Raes K., Tjwa M., Eriksson U., Shibuya M., Nuydens R., Van Den Bosch L., Meert T., D'Hooge R., Sendtner M., Robberecht W., Carmeliet P. Novel role for vascular endothelial growth factor (VEGF) receptor-1 and its ligand VEGF-B in motor neuron degeneration. J. Neurosci. Off. J. Soc. Neurosci. 2008, 28:10451-10459.
160. Polymenidou M., Lagier-Tourenne C., Hutt K.R., Huelga S.C., Moran J., Liang T.Y., Ling S.C., Sun E., Wancewicz E., Mazur C., Kordasiewicz H., Sedaghat Y., Donohue J.P., Shiue L., Bennett C.F., Yeo G.W., Cleveland D.W. Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43. Nat. Neurosci. 2011, 14:459-468.
161. Pramatarova A., Laganiere J., Roussel J., Brisebois K., Rouleau G.A. Neuron-specific expression of mutant superoxide dismutase 1 in transgenic mice does not lead to motor impairment. J. Neurosci. Off. J. Soc. Neurosci. 2001, 21:3369-3374.
162. Ralph G.S., Radcliffe P.A., Day D.M., Carthy J.M., Leroux M.A., Lee D.C., Wong L.F., Bilsland L.G., Greensmith L., Kingsman S.M., Mitrophanous K.A., Mazarakis N.D., Azzouz M. Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model. Nat. Med. 2005, 11:429-433.
163. Raoul C., Abbas-Terki T., Bensadoun J.C., Guillot S., Haase G., Szulc J., Henderson C.E., Aebischer P. Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS. Nat. Med. 2005, 11:423-428.
164. Reddy K., Zamiri B., Stanley S.Y., Macgregor R.B., Pearson C.E. The disease-associated r(GGGGCC)n repeat from the C9orf72 gene forms tract length-dependent uni- and multimolecular RNA G-quadruplex structures. J. Biol. Chem. 2013, 288:9860-9866.
165. Renton A.E., Majounie E., Waite A., Simon-Sanchez J., Rollinson S., Gibbs J.R., Schymick J.C., Laaksovirta H., van Swieten J.C., Myllykangas L., Kalimo H., Paetau A., Abramzon Y., Remes A.M., Kaganovich A., Scholz S.W., Duckworth J., Ding J., Harmer D.W., Hernandez D.G., Johnson J.O., Mok K., Ryten M., Trabzuni D., Guerreiro R.J., Orrell R.W., Neal J., Murray A., Pearson J., Jansen I.E., Sondervan D., Seelaar H., Blake D., Young K., Halliwell N., Callister J.B., Toulson G., Richardson A., Gerhard A., Snowden J., Mann D., Neary D., Nalls M.A., Peuralinna T., Jansson L., Isoviita V.M., Kaivorinne A.L., Holtta-Vuori M., Ikonen E., Sulkava R., Benatar M., Wuu J., Chio A., Restagno G., Borghero G., Sabatelli M., Consortium I., Heckerman D., Rogaeva E., Zinman L., Rothstein J.D., Sendtner M., Drepper C., Eichler E.E., Alkan C., Abdullaev Z., Pack S.D., Dutra A., Pak E., Hardy J., Singleton A., Williams N.M., Heutink P., Pickering-Brown S., Morris H.R., Tienari P.J., Traynor B.J. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 2011, 72:257-268.
166. Renton A.E., Chio A., Traynor B.J. State of play in amyotrophic lateral sclerosis genetics. Nat. Neurosci. 2014, 17:17-23.
167. Ringholz G.M., Appel S.H., Bradshaw M., Cooke N.A., Mosnik D.M., Schulz P.E. Prevalence and patterns of cognitive impairment in sporadic ALS. Neurology 2005, 65:586-590.
168. Rizvanov A.A., Mukhamedyarov M.A., Palotas A., Islamov R.R. Retrogradely transported siRNA silences human mutant SOD1 in spinal cord motor neurons. Exp. Brain Res. 2009, 195:1-4.
169. Robberecht W., Philips T. The changing scene of amyotrophic lateral sclerosis. Nat. Rev. Neurosci. 2013, 14:248-264.
170. Rothstein J.D., Van Kammen M., Levey A.I., Martin L.J., Kuncl R.W. Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann. Neurol. 1995, 38:73-84.
171. Rothstein J.D., Patel S., Regan M.R., Haenggeli C., Huang Y.H., Bergles D.E., Jin L., Dykes Hoberg M., Vidensky S., Chung D.S., Toan S.V., Bruijn L.I., Su Z.Z., Gupta P., Fisher P.B. Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature 2005, 433:73-77.
172. Sareen D., O'Rourke J.G., Meera P., Muhammad A.K., Grant S., Simpkinson M., Bell S., Carmona S., Ornelas L., Sahabian A., Gendron T., Petrucelli L., Baughn M., Ravits J., Harms M.B., Rigo F., Bennett C.F., Otis T.S., Svendsen C.N., Baloh R.H. Targeting RNA foci in iPSC-derived motor neurons from ALS patients with a C9ORF72 repeat expansion. Sci. Transl. Med. 2013, 5:208ra149.
173. Sasaki S., Iwata M. Mitochondrial alterations in the spinal cord of patients with sporadic amyotrophic lateral sclerosis. J. Neuropathol. Exp. Neurol. 2007, 66:10-16.
174. Sasaki S., Maruyama S. Increase in diameter of the axonal initial segment is an early change in amyotrophic lateral sclerosis. J. Neurol. Sci. 1992, 110:114-120.
175. Schwab M.E. Functions of Nogo proteins and their receptors in the nervous system. Nat. Rev. Neurosci. 2010, 11:799-811.
176. Scott S., Kranz J.E., Cole J., Lincecum J.M., Thompson K., Kelly N., Bostrom A., Theodoss J., Al-Nakhala B.M., Vieira F.G., Ramasubbu J., Heywood J.A. Design, power, and interpretation of studies in the standard murine model of ALS. Amyotroph. Lateral Scler. Off. Publ. World Fed. Neurol. Res. Group Mot. Neuron Dis. 2008, 9:4-15.
177. Shefner J.M., Cudkowicz M.E., Schoenfeld D., Conrad T., Taft J., Chilton M., Urbinelli L., Qureshi M., Zhang H., Pestronk A., Caress J., Donofrio P., Sorenson E., Bradley W., Lomen-Hoerth C., Pioro E., Rezania K., Ross M., Pascuzzi R., Heiman-Patterson T., Tandan R., Mitsumoto H., Rothstein J., Smith-Palmer T., MacDonald D., Burke D., Consortium N. A clinical trial of creatine in ALS. Neurology 2004, 63:1656-1661.
178. Smith R.A., Miller T.M., Yamanaka K., Monia B.P., Condon T.P., Hung G., Lobsiger C.S., Ward C.M., McAlonis-Downes M., Wei H., Wancewicz E.V., Bennett C.F., Cleveland D.W. Antisense oligonucleotide therapy for neurodegenerative disease. J. Clin. Invest. 2006, 116:2290-2296.
179. Staats K.A., Hernandez S., Schonefeldt S., Bento-Abreu A., Dooley J., Van Damme P., Liston A., Robberecht W., Van Den Bosch L. Rapamycin increases survival in ALS mice lacking mature lymphocytes. Mol. Neurodegener. 2013, 8:31.
180. Stockmann M., Meyer-Ohlendorf M., Achberger K., Putz S., Demestre M., Yin H., Hendrich C., Linta L., Heinrich J., Brunner C., Proepper C., Kuh G.F., Baumann B., Langer T., Schwalenstocker B., Braunstein K.E., von Arnim C., Schneuwly S., Meyer T., Wong P.C., Boeckers T.M., Ludolph A.C., Liebau S. The dynactin p150 subunit: cell biology studies of sequence changes found in ALS/MND and Parkinsonian syndromes. J. Neural Transm. 2013, 120:785-798.
181. Storkebaum E., Lambrechts D., Dewerchin M., Moreno-Murciano M.P., Appelmans S., Oh H., Van Damme P., Rutten B., Man W.Y., De Mol M., Wyns S., Manka D., Vermeulen K., Van Den Bosch L., Mertens N., Schmitz C., Robberecht W., Conway E.M., Collen D., Moons L., Carmeliet P. Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS. Nat. Neurosci. 2005, 8:85-92.
182. Sunyach C., Michaud M., Arnoux T., Bernard-Marissal N., Aebischer J., Latyszenok V., Gouarne C., Raoul C., Pruss R.M., Bordet T., Pettmann B. Olesoxime delays muscle denervation, astrogliosis, microglial activation and motoneuron death in an ALS mouse model. Neuropharmacology 2012, 62:2346-2352.
183. Suzuki M., Svendsen C.N. Combining growth factor and stem cell therapy for amyotrophic lateral sclerosis. Trends Neurosci. 2008, 31:192-198.
184. Suzuki M., McHugh J., Tork C., Shelley B., Klein S.M., Aebischer P., Svendsen C.N. GDNF secreting human neural progenitor cells protect dying motor neurons, but not their projection to muscle, in a rat model of familial ALS. PLoS One 2007, 2:e689.
185. Suzuki M., McHugh J., Tork C., Shelley B., Hayes A., Bellantuono I., Aebischer P., Svendsen C.N. Direct muscle delivery of GDNF with human mesenchymal stem cells improves motor neuron survival and function in a rat model of familial ALS. Mol. Ther. J. Am. Soc. Gene Ther. 2008, 16:2002-2010.
186. Taes I., Timmers M., Hersmus N., Bento-Abreu A., Van Den Bosch L., Van Damme P., Auwerx J., Robberecht W. Hdac6 deletion delays disease progression in the SOD1G93A mouse model of ALS. Hum. Mol. Genet. 2013, 22:1783-1790.
187. Takahashi K., Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006, 126:663-676.
188. Tan W., Naniche N., Bogush A., Pedrini S., Trotti D., Pasinelli P. Small peptides against the mutant SOD1/Bcl-2 toxic mitochondrial complex restore mitochondrial function and cell viability in mutant SOD1-mediated ALS. J. Neurosci. Off. J. Soc. Neurosci. 2013, 33:11588-11598.
189. Thau N., Knippenberg S., Korner S., Rath K.J., Dengler R., Petri S. Decreased mRNA expression of PGC-1alpha and PGC-1alpha-regulated factors in the SOD1G93A ALS mouse model and in human sporadic ALS. J. Neuropathol. Exp. Neurol. 2012, 71:1064-1074.
190. Tian F., Morimoto N., Liu W., Ohta Y., Deguchi K., Miyazaki K., Abe K. In vivo optical imaging of motor neuron autophagy in a mouse model of amyotrophic lateral sclerosis. Autophagy 2011, 7:985-992.
191. Tradewell M.L., Yu Z., Tibshirani M., Boulanger M.C., Durham H.D., Richard S. Arginine methylation by PRMT1 regulates nuclear-cytoplasmic localization and toxicity of FUS/TLS harbouring ALS-linked mutations. Hum. Mol. Genet. 2012, 21:136-149.
192. Traynor B.J., Alexander M., Corr B., Frost E., Hardiman O. Effect of a multidisciplinary amyotrophic lateral sclerosis (ALS) clinic on ALS survival: a population based study, 1996-2000. J. Neurol. Neurosurg. Psychiatry 2003, 74:1258-1261.
193. Turner M.R., Cagnin A., Turkheimer F.E., Miller C.C., Shaw C.E., Brooks D.J., Leigh P.N., Banati R.B. Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis: an [11C](R)-PK11195 positron emission tomography study. Neurobiol. Dis. 2004, 15:601-609.
194. Urushitani M., Ezzi S.A., Julien J.P. Therapeutic effects of immunization with mutant superoxide dismutase in mice models of amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:2495-2500.
195. Van Damme P., Robberecht W. Recent advances in motor neuron disease. Curr. Opin. Neurol. 2009, 22:486-492.
196. Van Damme P., Bogaert E., Dewil M., Hersmus N., Kiraly D., Scheveneels W., Bockx I., Braeken D., Verpoorten N., Verhoeven K., Timmerman V., Herijgers P., Callewaert G., Carmeliet P., Van Den Bosch L., Robberecht W. Astrocytes regulate GluR2 expression in motor neurons and their vulnerability to excitotoxicity. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:14825-14830.
197. Van Den Bosch L., Tilkin P., Lemmens G., Robberecht W. Minocycline delays disease onset and mortality in a transgenic model of ALS. Neuroreport 2002, 13:1067-1070.
198. Van Den Bosch L., Storkebaum E., Vleminckx V., Moons L., Vanopdenbosch L., Scheveneels W., Carmeliet P., Robberecht W. Effects of vascular endothelial growth factor (VEGF) on motor neuron degeneration. Neurobiol. Dis. 2004, 17:21-28.
199. Van Hoecke A., Schoonaert L., Lemmens R., Timmers M., Staats K.A., Laird A.S., Peeters E., Philips T., Goris A., Dubois B., Andersen P.M., Al-Chalabi A., Thijs V., Turnley A.M., van Vught P.W., Veldink J.H., Hardiman O., Van Den Bosch L., Gonzalez-Perez P., Van Damme P., Brown R.H., van den Berg L.H., Robberecht W. EPHA4 is a disease modifier of amyotrophic lateral sclerosis in animal models and in humans. Nat. Med. 2012, 18:1418-1422.
200. Vance C., Rogelj B., Hortobagyi T., De Vos K.J., Nishimura A.L., Sreedharan J., Hu X., Smith B., Ruddy D., Wright P., Ganesalingam J., Williams K.L., Tripathi V., Al-Saraj S., Al-Chalabi A., Leigh P.N., Blair I.P., Nicholson G., de Belleroche J., Gallo J.M., Miller C.C., Shaw C.E. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science 2009, 323:1208-1211.
201. Wang Y., Mao X.O., Xie L., Banwait S., Marti H.H., Greenberg D.A., Jin K. Vascular endothelial growth factor overexpression delays neurodegeneration and prolongs survival in amyotrophic lateral sclerosis mice. J. Neurosci. Off. J. Soc. Neurosci. 2007, 27:304-307.
202. Wang W., Li L., Lin W.L., Dickson D.W., Petrucelli L., Zhang T., Wang X. The ALS disease-associated mutant TDP-43 impairs mitochondrial dynamics and function in motor neurons. Hum. Mol. Genet. 2013, 22:4706-4719.
203. Williamson T.L., Cleveland D.W. Slowing of axonal transport is a very early event in the toxicity of ALS-linked SOD1 mutants to motor neurons. Nat. Neurosci. 1999, 2:50-56.
204. Wong E., Cuervo A.M. Autophagy gone awry in neurodegenerative diseases. Nat. Neurosci. 2010, 13:805-811.
205. Wong P.C., Pardo C.A., Borchelt D.R., Lee M.K., Copeland N.G., Jenkins N.A., Sisodia S.S., Cleveland D.W., Price D.L. An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Neuron 1995, 14:1105-1116.
206. Xu Y.F., Gendron T.F., Zhang Y.J., Lin W.L., D'Alton S., Sheng H., Casey M.C., Tong J., Knight J., Yu X., Rademakers R., Boylan K., Hutton M., McGowan E., Dickson D.W., Lewis J., Petrucelli L. Wild-type human TDP-43 expression causes TDP-43 phosphorylation, mitochondrial aggregation, motor deficits, and early mortality in transgenic mice. J. Neurosci. Off. J. Soc. Neurosci. 2010, 30:10851-10859.
207. Yamamoto A., Lucas J.J., Hen R. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell 2000, 101:57-66.
208. Yamanaka K., Chun S.J., Boillee S., Fujimori-Tonou N., Yamashita H., Gutmann D.H., Takahashi R., Misawa H., Cleveland D.W. Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis. Nat. Neurosci. 2008, 11:251-253.
209. Yanagisawa N., Shindo M. [Neuroprotective therapy for amyotrophic lateral sclerosis (ALS)]. Rinsho Shinkeigaku Clin. Neurol. 1996, 36:1329-1330.
210. Yoo Y.E., Ko C.P. Treatment with trichostatin A initiated after disease onset delays disease progression and increases survival in a mouse model of amyotrophic lateral sclerosis. Exp. Neurol. 2011, 231:147-159.
211. Zhang B., Tu P., Abtahian F., Trojanowski J.Q., Lee V.M. Neurofilaments and orthograde transport are reduced in ventral root axons of transgenic mice that express human SOD1 with a G93A mutation. J. Cell Biol. 1997, 139:1307-1315.
212. Zhang X., Li L., Chen S., Yang D., Wang Y., Zhang X., Wang Z., Le W. Rapamycin treatment augments motor neuron degeneration in SOD1(G93A) mouse model of amyotrophic lateral sclerosis. Autophagy 2011, 7:412-425.
213. Zhang Y., Cook A., Kim J., Baranov S.V., Jiang J., Smith K., Cormier K., Bennett E., Browser R.P., Day A.L., Carlisle D.L., Ferrante R.J., Wang X., Friedlander R.M. Melatonin inhibits the caspase-1/cytochrome c/caspase-3 cell death pathway, inhibits MT1 receptor loss and delays disease progression in a mouse model of amyotrophic lateral sclerosis. Neurobiol. Dis. 2013, 55:26-35.
214. Zhang Z., Almeida S., Lu Y., Nishimura A.L., Peng L., Sun D., Wu B., Karydas A.M., Tartaglia M.C., Fong J.C., Miller B.L., Farese R.V., Moore M.J., Shaw C.E., Gao F.B. Downregulation of microRNA-9 in iPSC-derived neurons of FTD/ALS patients with TDP-43 mutations. PLoS One 2013, 8:e76055.
215. Zhang X., Chen S., Song L., Tang Y., Shen Y., Jia L., Le W. MTOR-independent, autophagic enhancer trehalose prolongs motor neuron survival and ameliorates the autophagic flux defect in a mouse model of amyotrophic lateral sclerosis. Autophagy 2014, 10.
216. Zhao W., Varghese M., Yemul S., Pan Y., Cheng A., Marano P., Hassan S., Vempati P., Chen F., Qian X., Pasinetti G.M. Peroxisome proliferator activator receptor gamma coactivator-1alpha (PGC-1alpha) improves motor performance and survival in a mouse model of amyotrophic lateral sclerosis. Mol. Neurodegener. 2011, 6:51.
217. Zheng C., Skold M.K., Li J., Nennesmo I., Fadeel B., Henter J.I. VEGF reduces astrogliosis and preserves neuromuscular junctions in ALS transgenic mice. Biochem. Biophys. Res. Commun. 2007, 363:989-993.
218. Zhu S., Stavrovskaya I.G., Drozda M., Kim B.Y., Ona V., Li M., Sarang S., Liu A.S., Hartley D.M., Wu D.C., Gullans S., Ferrante R.J., Przedborski S., Kristal B.S., Friedlander R.M. Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature 2002, 417:74-78.
219. Zinszner H., Sok J., Immanuel D., Yin Y., Ron D. TLS (FUS) binds RNA in vivo and engages in nucleo-cytoplasmic shuttling. J. Cell Sci. 1997, 110(Pt 15):1741-1750.
220. Zu T., Duvick L.A., Kaytor M.D., Berlinger M.S., Zoghbi H.Y., Clark H.B., Orr H.T. Recovery from polyglutamine-induced neurodegeneration in conditional SCA1 transgenic mice. J. Neurosci. Off. J. Soc. Neurosci. 2004, 24:8853-8861.